BCL2 and diffuse large B-cell lymphoma: DLBCL has been extensively characterized at the genetic, biochemical and oncogenomic level [9-11], contributing to our current understanding that DLBCL is a heterogeneous disease that (i) is comprised of different histopathologic, genetic and molecular subtypes, (ii) requires different approaches to therapy and patient management and iii) exhibits different outcomes in accordance with BCL2 expression [12], occurrence of MYC-activating chromosomal translocations [13], cytogenetic complexity [14] and patient age at diagnosis [15] – to name but a few prognostic parameters.